status: 200
content-location: http://rest.kegg.jp/get/path:map05220
server: Apache
date: Wed, 15 Oct 2014 14:59:11 GMT
content-type: text/plain

ENTRY       map05220                    Pathway
NAME        Chronic myeloid leukemia
DESCRIPTION Chronic myelogenous leukemia (CML) originates in a pluripotent hematopoetic stem cell of the bone marrow and is characterized by greatly increased numbers of granulocytes in the blood. Myeloid and other hematopoetic cell lineages are involved in the process of clonal proliferation and differentiation. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22.  The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.
CLASS       Human Diseases; Cancers
PATHWAY_MAP map05220  Chronic myeloid leukemia
DISEASE     H00004  Chronic myeloid leukemia (CML)
REFERENCE   PMID:15719031
  AUTHORS   Ren R.
  TITLE     Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
  JOURNAL   Nat Rev Cancer 5:172-83 (2005)
REFERENCE   PMID:11071626
  AUTHORS   Deininger MW, Goldman JM, Melo JV.
  TITLE     The molecular biology of chronic myeloid leukemia.
  JOURNAL   Blood 96:3343-56 (2000)
REFERENCE   PMID:14982876
  AUTHORS   Calabretta B, Perrotti D.
  TITLE     The biology of CML blast crisis.
  JOURNAL   Blood 103:4010-22 (2004)
REFERENCE   PMID:10403855
  AUTHORS   Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
  TITLE     The biology of chronic myeloid leukemia.
  JOURNAL   N Engl J Med 341:164-72 (1999)
REFERENCE   PMID:15156182
  AUTHORS   Mitani K.
  TITLE     Molecular mechanisms of leukemogenesis by AML1/EVI-1.
  JOURNAL   Oncogene 23:4263-9 (2004)
REFERENCE   PMID:16484590
  AUTHORS   Dong M, Blobe GC.
  TITLE     Role of transforming growth factor-beta in hematologic malignancies.
  JOURNAL   Blood 107:4589-96 (2006)
REFERENCE   PMID:9834202
  AUTHORS   Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.
  TITLE     The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
  JOURNAL   Blood 92:4003-12 (1998)
REFERENCE   PMID:12801837
  AUTHORS   Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
  TITLE     p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
  JOURNAL   Haematologica 88:622-30 (2003)
REFERENCE   PMID:11160144
  AUTHORS   Baldwin AS.
  TITLE     Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.
  JOURNAL   J Clin Invest 107:241-6 (2001)
REFERENCE   PMID:12244301
  AUTHORS   Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL.
  TITLE     PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
  JOURNAL   Nat Med 8:1145-52 (2002)
REFERENCE   PMID:22286129
  AUTHORS   Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V
  TITLE     BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
  JOURNAL   Nat Chem Biol 8:285-93 (2012)
KO_PATHWAY  ko05220
///
